Menu Search
Equities

4Sc AG

VSC:DUS

4Sc AG

Actions
  • Price (EUR)5.50
  • Today's Change0.00 / 0.00%
  • Shares traded190.00
  • 1 Year change-27.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.

  • Revenue in EUR (TTM)359.00k
  • Net income in EUR-7.53m
  • Incorporated2000
  • Employees15.00
  • Location
    4Sc AGFraunhoferstr. 22PLANEGG 82152GermanyDEU
  • Phone+49 897007630
  • Fax+49 8 970076329
  • Websitehttps://www.4sc.de
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.